Literature DB >> 11699078

Crystalloid and colloid resuscitation of uncontrolled hemorrhagic shock following massive splenic injury.

M M Krausz1, Y Bashenko, M Hirsh.   

Abstract

Using a standardized massive splenic injury (MSI) model of uncontrolled hemorrhagic shock we studied the effect of vigorous crystalloid or colloid fluid resuscitation on the hemodynamic response, and survival in rats. The value of massive fluid infusion in uncontrolled hemorrhagic shock following intra-abdominal solid organ injury is still controversial. The effect of crystalloid and colloid infusion was studied following massive splenic injury. The animals were randomized into six groups: group 1 (n = 8) sham-operated, group 2 (n = 12) MSI untreated, group 3 (n = 10) MSI treated with 41.5 mL/kg Ringer's lactate (large-volume Ringer's lactate, LVRL), group 4 (n = 14) MSI treated with 5 mL/kg 7.5% NaCl (hypertonic saline, HTS), group 5 (n = 10) MSI treated with 7.5 mL/kg hydroxyethyl starch (HES-7.5), and group 6 (n = 11) MSI treated with 15 mL/kg hydroxyethyl starch (HES-15). Following MSI mean arterial pressure (MAP) in untreated group 2 decreased from 109.1 +/- 4.5 to 49.8 +/- 9.6 mmHg (P < 0.001) in 60 min. Mean survival time was 132.1 +/- 18.7 min, and total blood loss was 30.2 +/- 4.1% of blood volume. LVRL infusion resulted in an early rise in MAP from 59.7 +/- 7.3 to 90.0 +/- 11.3 mmHg (P < 0.01), which then rapidly dropped to 11.7 +/- 4.5 mmHg (P < 0.001) after 60 min. The mean survival time was 82.5 +/- 18.2 min (P < 0.01), and total blood loss was 53.7 +/- 2.9% (P < 0.01). Total blood loss following HTS infusion was 32.2 +/- 4.0% and survival time was 127.9 +/- 19.7 min. HES-7.5 infusion only moderately increased bleeding to 44.2 +/- 3.9% (P < 0.05), but mortality remained unchanged. HES-15 infusion resulted in an increase in blood loss to 47.8 +/- 7.1% (0.01), survival time dropped to 100.7 +/- 12.3 min (P < 0.05). Vigorous large volume infusion of Ringer's lactate or HES following MSI resulted in a significant increase in intra-abdominal bleeding and shortened survival time compared to untreated, small volume HTS, or HES-7.5-treated animals. The hemodynamic response to crystalloid or colloid infusion in blunt abdominal trauma is primarily dependent on the severity of injury and the rate of fluid resuscitation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11699078     DOI: 10.1097/00024382-200116050-00011

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  7 in total

Review 1.  Capnometry in the prehospital setting: are we using its potential?

Authors:  Dejan Kupnik; Pavel Skok
Journal:  Emerg Med J       Date:  2007-09       Impact factor: 2.740

Review 2.  [The preclinical care of polytraumatized patients].

Authors:  J Döhnert; B Auerbach; W Wyrwich; C E Heyde
Journal:  Orthopade       Date:  2005-09       Impact factor: 1.087

Review 3.  Colloid solutions: a clinical update.

Authors:  Tomi T Niemi; Ryo Miyashita; Michiaki Yamakage
Journal:  J Anesth       Date:  2010-10-17       Impact factor: 2.078

Review 4.  Fluid resuscitation: past, present, and the future.

Authors:  Heena P Santry; Hasan B Alam
Journal:  Shock       Date:  2010-03       Impact factor: 3.454

5.  Transfusion protocol in trauma.

Authors:  Paramjit Kaur; Sabita Basu; Gagandeep Kaur; Ravneet Kaur
Journal:  J Emerg Trauma Shock       Date:  2011-01

6.  A comparison of vasopressin, terlipressin, and lactated ringers for resuscitation of uncontrolled hemorrhagic shock in an animal model.

Authors:  Chien-Chang Lee; Meng-Tse Gabriel Lee; Shy-Shin Chang; Si-Huei Lee; Yu-Chi Huang; Chia-Hung Yo; Shih-Hao Lee; Shyr-Chyr Chen
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

7.  Resuscitation Using Liposomal Vasopressin in an Animal Model of Uncontrolled Hemorrhagic Shock.

Authors:  Meng-Tse Gabriel Lee; Hsuan-Mao Wang; Ja-An Annie Ho; Nien-Chu Fan; Ya-Lin Yang; Chien-Chang Lee; Shyr-Chyr Chen
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.